Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone cardiovascular outcomes study in type 2 diabetes with diabetic kidney disease
NL-OMON47393Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary cardiovascular composite endpoint. Started Dec 2015; status: active, not recruiting.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON47393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47393.